Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Positive phase III data for Merck diabetes drug
Additionally, treatment with Januvia improved measures of beta cell function. Beta cells are cells in the pancreas that make and release insulin. The data from the studies were
Additionally, treatment with Januvia improved measures of beta cell function. Beta cells are cells in the pancreas that make and release insulin. The data from the studies were
The FDA has requested additional safety information on Trexima, which may require new studies. Pozen and GSK said that they intend to request a meeting with the FDA
A novel insulin sensitizer, metaglidasen has been shown in a previously conducted phase II trial in patients with diabetes to be well tolerated and to lower blood glucose,
The data, presented at the American Diabetes Association's annual scientific sessions, show that WelChol treatment resulted in a mean 0.5% reduction in A1C versus placebo. Moreover, in patients
To date, regular reviews of safety data for the trial have revealed no serious drug side effects from NX-1207 treatment. The Independent Data Monitoring Committee for the trial
Zetia is the first in a class of cholesterol-lowering agents that inhibits the intestinal absorption of cholesterol through a unique mechanism of action. With this new indication, Zetia
Currently, Velcade has been approved by the FDA for the treatment of multiple myeloma patients who have received at least one prior therapy. To date, over 33,000 multiple
Gleevec, currently used to treat a number of cancers including chronic myelogenous leukemia, destroyed tumors in the study by cutting of the blood supply to them. The results
The new dosing strengths, 5/40mg and 10/40mg, combine the calcium channel blocker (CCB) amlodipine with the highest available dose of the ACE inhibitor benazepril. According to Novartis, Lotrel
The combined company, which will operate under the “PharmAthene” name, is expected to be a leader in biodefense featuring a substantial portfolio of procurement-stage biodefense products targeting anthrax,